# INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)

- Source: PR Newswire M&A
- Published: 2026-10-30T22:01:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/inovio-announces-fda-accelerated-approval-of-voceryq-an-immunotherapy-to-reduce-the-frequency-of-surgery-in-adults-with-recurrent-respiratory-papillomatosis-rrp-302925406.html
- Canonical: https://groundlevelnews.com/story/inovio-announces-fda-accelerated-approval-of-voceryq-an-immunotherapy--5eb679/

INOVIO delivers a new nonsurgical treatment option with a broad indication for adults living with RRP, a rare and debilitating disease that often requires surgery VOCERYQ™ is a plasmid DNA-based immunotherapy that targets the root cause of RRP: HPV-6 and HPV-11 INOVIO expects to make...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._